FDA, Wegovy
New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
These include knockoffs of popular weight loss drugs. Customs officials allowed CBS News a rare look into their operations ... that Novo Nordisk is the only company in the U.S. with ...
People on MSN3d
Mom Overdosed on Weight Loss Drug She Got on Instagram, Recalls 'Throwing Up Blood': 'Thought I Was Going to Die'Leigh-Anne Lagden, 26, opened up about being hospitalized after accidentally overdosing on knockoff weight loss injections ...
News Nation on MSN1d
Ozempic can lead to muscle mass loss: StudyRecent studies have found that Ozempic could lead to more muscle mass loss than traditional weight loss methods.
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
But when the FDA finally gave pharmaceutical companies approval to use these same drugs for weight loss, demand for ...
Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...
GoodRx has officially entered the weight loss drug market by offering ... according to an Oct. 29 news release. The FDA approved Qsymia (phentermine and topiramate) for chronic weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback